TrialBMC pharmacology & toxicology2014

Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®.

Davide Crobu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.